PH12022550081A1 - Ehrlichia vaccines and immunogenic compositions - Google Patents

Ehrlichia vaccines and immunogenic compositions

Info

Publication number
PH12022550081A1
PH12022550081A1 PH1/2022/550081A PH12022550081A PH12022550081A1 PH 12022550081 A1 PH12022550081 A1 PH 12022550081A1 PH 12022550081 A PH12022550081 A PH 12022550081A PH 12022550081 A1 PH12022550081 A1 PH 12022550081A1
Authority
PH
Philippines
Prior art keywords
ehrlichia
immunogenic compositions
vaccines
adjuvant
immunogenic
Prior art date
Application number
PH1/2022/550081A
Other languages
English (en)
Inventor
Paul J Dominowski
Suman Mahan
Jere W Mcbride
Jason J Millership
Duncan M Mwangi
Sharath Rai
Sharon M Wappel
Original Assignee
Res Found Dev
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Found Dev, Zoetis Services Llc filed Critical Res Found Dev
Publication of PH12022550081A1 publication Critical patent/PH12022550081A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1246—Rickettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PH1/2022/550081A 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions PH12022550081A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962873843P 2019-07-12 2019-07-12
US201962879762P 2019-07-29 2019-07-29
US202063049476P 2020-07-08 2020-07-08
PCT/US2020/041779 WO2021011456A1 (en) 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions

Publications (1)

Publication Number Publication Date
PH12022550081A1 true PH12022550081A1 (en) 2023-04-12

Family

ID=71948757

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550081A PH12022550081A1 (en) 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions

Country Status (11)

Country Link
US (1) US12624093B2 (enExample)
EP (1) EP3996741A1 (enExample)
JP (1) JP2022540197A (enExample)
CN (1) CN114514238A (enExample)
AU (1) AU2020314625A1 (enExample)
BR (1) BR112022000347A2 (enExample)
CA (1) CA3146842A1 (enExample)
CL (1) CL2022000086A1 (enExample)
MX (1) MX2022000525A (enExample)
PH (1) PH12022550081A1 (enExample)
WO (1) WO2021011456A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025118050A1 (pt) * 2023-12-04 2025-06-12 Laboratório Bio-Vet Ltda Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043085A (en) * 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
MXPA05004804A (es) 2002-11-04 2005-12-05 Res Dev Foundation Antigenos de p153 y p156 para el inmunodiagnostico de erliquiosis canina y humana y usos de los mismos.
CA2555413C (en) 2004-02-25 2013-12-17 Research Development Foundation An immunoreactive 38-kda ferric binding protein of ehrlichia canis and uses thereof
US20050202046A1 (en) 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
US7842474B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
EP3527582B1 (en) * 2005-04-04 2022-08-17 IDEXX Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
US8591906B2 (en) * 2005-06-16 2013-11-26 Research Development Foundation Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis
EP1790656A1 (en) 2005-11-25 2007-05-30 Nanokem S.A. Solution-phase synthesis of leuprolide
WO2008000070A1 (en) * 2006-06-27 2008-01-03 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
EP2064231B2 (en) 2006-08-31 2020-08-26 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
WO2009102509A2 (en) 2008-01-10 2009-08-20 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
CA2796563C (en) 2009-04-28 2018-05-22 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
HRP20181039T1 (hr) * 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
CA2874966C (en) * 2012-05-31 2020-06-09 Zoetis Services Llc Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections
SI3542819T1 (sl) 2013-05-14 2021-11-30 Zoetis Services Llc Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
KR20200039025A (ko) 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
MX2020011887A (es) 2018-05-07 2021-03-29 Res Found Dev Polipéptidos inmunorreactivos.
AU2019311181A1 (en) 2018-07-27 2021-02-18 Research Development Foundation Chimeric immunogenic polypeptides

Also Published As

Publication number Publication date
BR112022000347A2 (pt) 2022-04-12
CL2022000086A1 (es) 2022-09-30
JP2022540197A (ja) 2022-09-14
CN114514238A (zh) 2022-05-17
AU2020314625A1 (en) 2022-02-03
EP3996741A1 (en) 2022-05-18
WO2021011456A1 (en) 2021-01-21
MX2022000525A (es) 2022-04-20
CA3146842A1 (en) 2021-01-21
US20220356231A1 (en) 2022-11-10
US12624093B2 (en) 2026-05-12

Similar Documents

Publication Publication Date Title
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
PH12017502233A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
WO2017096341A3 (en) Adenovirus-vectored multivalent vaccine
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
NZ717594A (en) Oil-based adjuvants
PH12018500127A1 (en) Vaccine compositions
PH12021550484A1 (en) Immunological adjuvant and vaccine composition including sting agonist
EA201892735A1 (ru) Состав вакцины против hiv
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2021007502A (es) Formulaciones y métodos de vacuna de norovirus.
WO2016062020A9 (zh) 茯苓多糖活性组分和成分、其制备方法及用途
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EA201892003A1 (ru) Лечение атопического дерматита собак
MX2021010348A (es) Composiciones de lawsonia intracellularis y metodos de uso de las mismas.
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
CL2022000086A1 (es) Vacunas contra ehrlichia y composiciones inmunogénicas
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene
WO2020227605A3 (en) Dna encoded il-36 gamma as an adjuvant
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
MX388528B (es) Vacuna que comprende toxoides de clostridium.
AU2019268149A1 (en) Live attenuated heterologous vaccine for Leptospira